Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Risérus, U.
Right arrow Articles by Karpe, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Risérus, U.
Right arrow Articles by Karpe, F.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 54:1379-1384, 2005
© 2005 by the American Diabetes Association, Inc.

Rosiglitazone Increases Indexes of Stearoyl-CoA Desaturase Activity in Humans

Link to Insulin Sensitization and the Role of Dominant-Negative Mutation in Peroxisome Proliferator-Activated Receptor-{gamma}

Ulf Risérus1, Garry D. Tan1, Barbara A. Fielding1, Matt J. Neville1, Jenny Currie1, David B. Savage2, V. Krishna Chatterjee2, Keith N. Frayn1, Stephen O’Rahilly2, and Fredrik Karpe1

1 Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, U.K
2 Department of Medicine, Addenbrooke’s Hospital, University of Cambridge, Cambridge, U.K

Fatty acid desaturases such as steaoryl-CoA desaturase (SCD) convert saturated to unsaturated fatty acids and are involved in lipogenesis. Observational and animal data suggest that SCD-1 activity is related to insulin sensitivity. However, the effects of insulin-sensitizing drugs on SCD gene expression and desaturase activities are unknown in humans. In a randomized, placebo-controlled, double-blind, crossover study, 24 subjects with type 2 diabetes and one subject with partial lipodystrophy and diabetes due to dominant-negative mutation in the peroxisome proliferator-activated receptor-{gamma} (PPAR{gamma}) gene (P467L) received placebo and rosiglitazone for 3 months. SCD gene expression in adipose tissue was determined in 23 subjects, and in a representative subgroup (n = 10) we assessed fatty acid composition in fasting plasma triglycerides to estimate SCD and {Delta}6- and {Delta}5-desaturase activity, using product-to-precursor indexes. SCD mRNA expression increased by 48% after rosiglitazone (P < 0.01). SCD and {Delta}5-desaturase but not {Delta}6-desaturase activity indexes were increased after rosiglitazone versus placebo (P < 0.01 and P < 0.05, respectively). The change in activity index but not the expression of SCD was associated with improved insulin sensitivity (r = 0.73, P < 0.05). In the P467L PPAR{gamma} carrier, SCD and {Delta}5-desaturase activity indexes were exceptionally low but were restored (52- and 15-fold increases, respectively) after rosiglitazone treatment. This study shows for the first time that rosiglitazone increases SCD activity indexes and gene expression in humans. An increased SCD activity index may reflect increased lipogenesis and might contribute to insulin sensitization by rosiglitazone. The restored SCD activity index after rosiglitazone in PPAR{gamma} mutation supports a pivotal role of PPAR{gamma} function in SCD regulation.

Address correspondence and reprint requests to Dr. Ulf Risérus, Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, OX3 7LJ, U.K. E-mail: ulf.riserus{at}oxlip.ox.ac.uk. or fredrik.karpe{at}academ.ox.ac.uk

Abbreviations: CLA, conjugated linoleic acid; HOMA%S, homeostasis model assessment of insulin sensitivity; NEFA, nonesterified fatty acid; PPAR{gamma}, peroxisome proliferator-activated receptor-{gamma}; P/S ratio, polyunsaturated-to-saturated fat ratio; SCD, steaoryl-CoA desaturase; TZD, thiazolidinedione


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
M. Kolak, H. Yki-Jarvinen, K. Kannisto, M. Tiikkainen, A. Hamsten, P. Eriksson, and R. M. Fisher
Effects of Chronic Rosiglitazone Therapy on Gene Expression in Human Adipose Tissue in Vivo in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., February 1, 2007; 92(2): 720 - 724.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
L. Wang, J. Huang, P. Saha, R. N. Kulkarni, M. Hu, Y. Kim, K. Park, L. Chan, A. S. Rajan, I. Lee, et al.
Orphan Receptor Small Heterodimer Partner Is an Important Mediator of Glucose Homeostasis
Mol. Endocrinol., November 1, 2006; 20(11): 2671 - 2681.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
H. J. Atherton, N. J. Bailey, W. Zhang, J. Taylor, H. Major, J. Shockcor, K. Clarke, and J. L. Griffin
A combined 1H-NMR spectroscopy- and mass spectrometry-based metabolomic study of the PPAR-{alpha} null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome
Physiol Genomics, October 11, 2006; 27(2): 178 - 186.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. B. Goldfine, S. Crunkhorn, M. Costello, H. Gami, E. J. Landaker, M. Niinobe, K. Yoshikawa, D. Lo, A. Warren, J. Jimenez-Chillaron, et al.
Necdin and E2F4 Are Modulated by Rosiglitazone Therapy in Diabetic Human Adipose and Muscle Tissue
Diabetes, March 1, 2006; 55(3): 640 - 650.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.